Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus eribulin in HR-positive/HER2-negative metastatic breast cancer
2016-004513-27Phase 2Active
- Sponsor
- MEDSIR
- Start
- Jul 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and eribulin in breast cancer, sponsored by MEDSIR. Primary endpoint: Clinical benefit rate (CBR) based on RECIST v1.1. Started Jul 2017; status: active.
02
Drugs
pembrolizumaberibulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004513-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004513-27.